LivaNova PLC is launching its Perceval "sutureless" surgical heart valve in the US this quarter following a Jan. 8 FDA approval. Sutureless valves offer the potential for a less invasive and quicker procedure compared to standard surgical aortic heart valve replacements, while potentially avoiding some disadvantages, such as paravalvular leakage, associated with even less invasive transcatheter aortic heart valves.
Clinical data supporting the LivaNova approval show a significant reduction in surgical procedure time in patients implanted with Perceval in both isolated and complex aortic valve replacements, according to LivaNova,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?